MKMats Koeneman

Mats Koeneman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mats Koeneman has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    How to Improve Pancreatic Cancer Network Care Using a Human-Centered Design Sprint

    by Jana S Hopstaken, Mats Koeneman, Robin Hooijer, Concha C van Rijssel, Theo van Voorthuizen, Frank A Oort, Charlotte F J M Blanken, Martijn de Groot, Cees J H M van Laarhoven, Martijn W J Stommel

    Pancreatic cancer is considered a complex cancer requiring specific expertise in diagnostic workup and multimodality treatment. Often, multiple health care providers in different hospitals are involved during patient care. This fragmentation of care challenges health care providers in the network to deliver efficient, coherent, and continuous network care. We performed a human-centered design (HCD) sprint in order to find means to improve network care for patients diagnosed with pancreatic cancer. The sprint comprised 5 days with different goals: empathize, define, ideate, prototype, and test. Experts and stakeholders were approached from the pancreatic cancer network to contribute. By using HCD, a goal was defined, various prototypes were explored, and one prototype was tested. The HCD Sprint led to a shared goal, which was to deliver pancreatic cancer network care in a (virtual) hospital in which there is “one narrative.” This means that the patient’s context and preferences are always clear and taken into account, care is characterized by a short time to diagnosis and treatment, and patient data are easily available for patients and involved clinicians. The accompanying prototypes were (1) network agreements, (2) patient itinerary, (3) transmural trajectory guidance, and (4) data sharing. For the latter, we developed and pilot-tested a real-time data sharing dashboard called CONNECT. The first pilot-test was promising and provided feedback for further development. In this viewpoint paper, we show that a HCD sprint is able to find possible means to improve pancreatic network care in a short time span. A real-time data sharing dashboard (CONNECT) was developed and pilot tested. The next steps include further development of the dashboard, implementation in our network, and long-term evaluation studies.


  • Open Access

    How to Improve Pancreatic Cancer Network Care: A Human Centered Design study (Preprint)

    by Jana S. Hopstaken, Mats Koeneman, Robin Hooijer, Concha C. van Rijssel, Theo van Voorthuizen, Frank A. Oort, Charlotte F.J.M. Blanken, Martijn de Groot, Cees J.H.M. van Laarhoven, Martijn W.J. Stommel

    BACKGROUND Pancreatic cancer is considered a complex cancer requiring specific expertise in diagnostic workup and multimodality treatment. Often multiple healthcare providers in different hospitals are involved during patient care. This fragmentation of care challenges healthcare providers in the network to deliver efficient, coherent and continuous network care. OBJECTIVE The aim of this study was to find means to improve network care for patients diagnosed with pancreatic cancer by applying a human centered design methodology. METHODS A Human Centered Design (HCD) Sprint was conducted in July 2020. The sprint comprised five days with different goals: Empathize, Define, Ideate, Prototype and Test. Experts and stakeholders were approached from the pancreatic cancer network to contribute. Patients and next of kin were interviewed about their experiences of network care prior to the Sprint. By using HCD a goal was defined, various prototypes were explored and one prototype was tested. RESULTS The HCD Sprint led to a shared goal which was to deliver pancreatic cancer network care in a (virtual) hospital in which there is ‘one narrative’. This means that the patient’s context and preferences are always clear and taken into account, care is characterized by a short time to diagnosis and treatment and patient data is easily available for patients and involved clinicians. The accompanying prototypes were 1) Network agreements 2) Patient Itinerary 3) Transmural Trajectory Guidance and 4) Data sharing. For the latter, we developed and pilot-tested a real-time data sharing dashboard CONNECT. The first pilot-test was promising and provided feedback for further development. CONCLUSIONS The HCD sprint resulted in several useful prototypes based on which a real-time data sharing dashboard (CONNECT) was developed and pilot tested. The next steps include further development of the dashboard, implementation in our network and long-term evaluation studies. CLINICALTRIAL not applicable

  • Open Access

    Comparing Continuous with Periodic Vital Sign Scoring for Clinical Deterioration Using a Patient Data Model

    by Roel V. Peelen, Yassin Eddahchouri, Mats Koeneman, René Melis, Harry van Goor, Sebastian J. H. Bredie

    To evaluate a minute-by-minute monitoring algorithm against a periodic early warning score (EWS) in detecting clinical deterioration and workload. Periodic EWSs suffer from large measurement intervals, causing late detection of deterioration. This might be prevented by continuous vital sign monitoring with a real-time algorithm such as the Visensia Safety Index (VSI). This prospective comparative data modeling cohort study (NCT04189653) compares continuous algorithmic alerts against periodic EWS in continuous monitored medical and surgical inpatients. We evaluated sensitivity, frequency, number of warnings needed to evaluate (NNE) and time of initial alert till escalation of care (EOC): Rapid Response Team activation, unplanned ICU admission, emergency surgery, or death. Also, the percentage of VSI alerting minutes was compared between patients with or without EOC. In 1529 admissions continuous VSI warned for 55% of EOC (95% CI: 45-64%) versus 51% (95% CI: 41-61%) by periodic EWS. NNE for VSI was 152 alerts per detected EOC (95% CI: 114-190) compared to 21 (95% CI: 17-28). It generated 0.99 warnings per day per patient compared to 0.13. Time from detection score till escalation was 8.3 hours (IQR: 2.6-24.8) with VSI versus 5.2 (IQR: 2.7-12.3) hours with EWS (P=0.074). The percentage of warning VSI minutes was higher in patients with EOC than in stable patients (2.36% vs 0.81%, P<0.001). Although sensitivity of detection was not significantly improved continuous vital sign monitoring shows potential for earlier alerts for deterioration compared to periodic EWS. A higher percentage of alerting minutes may indicate risk for deterioration.


  • Wearable Patch Heart Rate Variability Is an Early Marker of Systemic Inflammation During Experimental Human Endotoxemia

    by Mats Koeneman, Rebecca Koch, Harry van Goor, Peter Pickkers, Matthijs Kox, Sebastian Bredie

    Introduction: Early diagnosis and treatment can reduce the risk of organ failure and mortality in systemic inflammatory conditions. Heart rate variability (HRV) has potential for early identification of the onset of systemic inflammation, as it may detect changes in sympathetic nervous system activity resulting from the developing inflammatory response before clinical signs appear. With the use of new methodologies, we investigated the onset and kinetics of HRV changes as well as several inflammatory parameters and symptoms during experimental human endotoxemia, a model of systemic inflammation in humans in vivo. Patients and Methods: Healthy volunteers were intravenously administered LPS (n = 15) or placebo (n = 15). HRV was determined using a wireless wearable device, and parameters low to high frequency (LF:HF) ratio, root mean square of the successive differences (RMSSD), and standard deviation of normal-to-normal R-R intervals (SDNN)were calculated through 1-min-rolling 6-min windows. Plasma cytokine levels and flu-like symptoms and vital signs were serially assessed. Results: The increase in LF:HF ratio, reflecting sympathetic predominance, was more pronounced in the LPS group compared to the placebo group, with the difference becoming statistically significant 65 min following LPS administration (1.63 [1.42–1.83] vs. 1.28 [1.11–1.44], P = 0.005). Significant between-group differences in RMSSD and SDNN were observed from 127 to 140 min post-LPS administration onwards, respectively. Plasma cytokine levels showed significant between-group differences staring 60 min post-LPS. For symptom score, heart rate, temperature, and diastolic blood pressure, significant differences compared with the placebo group were observed at 90, 118, 120, and 124 min post-LPS, respectively. Conclusion: In a controlled human model of systemic inflammation, elevations in the LF:HF ratio followed very shortly after elevations in plasma cytokine levels and preceded onset of flu-like symptoms and alterations in vital signs. HRV may represent a promising non-invasive tool for early detection of a developing systemic inflammatory response.


  • Open Access

    Effect of Hypoglycemia on Heart Rate Variability in People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia

    by Mats Koeneman, Marleen Olde Bekkink, Lian van Meijel, Sebastian Bredie, Bastiaan de Galan

    People with impaired awareness of hypoglycemia (IAH) are at elevated risk of severe, potentially hazardous, hypoglycemia and would benefit from a device alerting to hypoglycemia. Heart rate variability (HRV) changes with hypoglycemia due to sympathetic activity. Since IAH is associated with suppressed sympathetic activity, we investigated whether hypoglycemia elicits a measurable change in HRV in patients with T1D and IAH. Eligible participants underwent a modified hyperinsulinemic euglycemic hypoglycemic clamp (glucose nadir, 43.1 ± 0.90 mg/dl), while HRV was measured by a VitalConnect HealthPatch. Measurements of HRV included Root Mean Square of the Successive Differences (RMSSD) and low to high frequency (LF:HF) ratio. Wilcoxon rank-sum test was used for testing within-subject HRV changes. We included 12 participants (8 female, mean age 57 ± 12 years, mean HbA1c 57 ± 5 mmol/mol (7.4 ± 0.4%)). Symptoms increased from 4.0 (1.5-7.0) at euglycemia to 7.5 (5.0-11.0) during hypoglycemia (P = .003). In response to hypoglycemia, the LF:HF ratio and RMSSD increased when normalized for data obtained during euglycemia (both P < .01). The LF:HF ratio increased in 6 participants (50%) and declined in one other participant (8%). The RMSSD decreased in 3 (25%) and increased in 4 (33%) participants. In 2 patients, no change in HRV could be detected in response to hypoglycemia. This study reveals that hypoglycemia-induced changes in HRV are retained in the majority of people with T1D and IAH, and that these changes can be detected by a wearable device. Real-time HRV seems usable for detection of hypoglycemia in patients with IAH.


  • Open Access

    Low compliance to a vital sign safety protocol on general hospital wards: A retrospective cohort study

    by Yassin Eddahchouri, Mats Koeneman, Manon Plokker, Egbert Brouwer, Tom H van de Belt, Harry van Goor, Sebastian Jh Bredie


  • Open Access

    Continuous Monitoring of Vital Signs in the General Ward Using Wearable Devices: Randomized Controlled Trial

    by Mariska Weenk, Sebastian J Bredie, Mats Koeneman, Gijs Hesselink, Harry van Goor, Tom H van de Belt

    Background: Wearable devices can be used for continuous patient monitoring in the general ward, increasing patient safety. Little is known about the experiences and expectations of patients and health care professionals regarding continuous monitoring with these devices.Objective: This study aimed to identify positive and negative effects as well as barriers and facilitators for the use of two wearable devices: ViSi Mobile (VM) and HealthPatch (HP).Methods: In this randomized controlled trial, 90 patients admitted to the internal medicine and surgical wards of a university hospital in the Netherlands were randomly assigned to continuous vital sign monitoring using VM or HP and a control group. Users’ experiences and expectations were addressed using semistructured interviews. Nurses, physician assistants, and medical doctors were also interviewed. Interviews were analyzed using thematic content analysis. Psychological distress was assessed using the State Trait Anxiety Inventory and the Pain Catastrophizing Scale. The System Usability Scale was used to assess the usability of both devices.Results: A total of 60 patients, 20 nurses, 3 physician assistants, and 6 medical doctors were interviewed. We identified 47 positive and 30 negative effects and 19 facilitators and 36 barriers for the use of VM and HP. Frequently mentioned topics included earlier identification of clinical deterioration, increased feelings of safety, and VM lines and electrodes. No differences related to psychological distress and usability were found between randomization groups or devices.Conclusions: Both devices were well received by most patients and health care professionals, and the majority of them encouraged the idea of monitoring vital signs continuously in the general ward. This comprehensive overview of barriers and facilitators of using wireless devices may serve as a guide for future researchers, developers, and health care institutions that consider implementing continuous monitoring in the ward.Trial Registration: Clinicaltrials.gov NCT02933307; http://clinicaltrials.gov/ct2/show/NCT02933307.


  • Open Access

    Continuous Monitoring of Vital Signs in the General Ward Using Wearable Devices: Randomized Controlled Trial (Preprint)

    by Mariska Weenk, Sebastian J Bredie, Mats Koeneman, Gijs Hesselink, Harry van Goor, Tom H van de Belt

    BACKGROUND Wearable devices can be used for continuous patient monitoring in the general ward, increasing patient safety. Little is known about the experiences and expectations of patients and health care professionals regarding continuous monitoring with these devices. OBJECTIVE This study aimed to identify positive and negative effects as well as barriers and facilitators for the use of two wearable devices: ViSi Mobile (VM) and HealthPatch (HP). METHODS In this randomized controlled trial, 90 patients admitted to the internal medicine and surgical wards of a university hospital in the Netherlands were randomly assigned to continuous vital sign monitoring using VM or HP and a control group. Users’ experiences and expectations were addressed using semistructured interviews. Nurses, physician assistants, and medical doctors were also interviewed. Interviews were analyzed using thematic content analysis. Psychological distress was assessed using the State Trait Anxiety Inventory and the Pain Catastrophizing Scale. The System Usability Scale was used to assess the usability of both devices. RESULTS A total of 60 patients, 20 nurses, 3 physician assistants, and 6 medical doctors were interviewed. We identified 47 positive and 30 negative effects and 19 facilitators and 36 barriers for the use of VM and HP. Frequently mentioned topics included earlier identification of clinical deterioration, increased feelings of safety, and VM lines and electrodes. No differences related to psychological distress and usability were found between randomization groups or devices. CONCLUSIONS Both devices were well received by most patients and health care professionals, and the majority of them encouraged the idea of monitoring vital signs continuously in the general ward. This comprehensive overview of barriers and facilitators of using wireless devices may serve as a guide for future researchers, developers, and health care institutions that consider implementing continuous monitoring in the ward. CLINICALTRIAL Clinicaltrials.gov NCT02933307; http://clinicaltrials.gov/ct2/show/NCT02933307.


  • Open Access

    Feasibility of a New Cuffless Device for Ambulatory Blood Pressure Measurement in Patients With Hypertension: Mixed Methods Study

    by Paula Am Ogink, Jelske M de Jong, Mats Koeneman, Mariska Weenk, Lucien Jlpg Engelen, Harry van Goor, Tom H van de Belt, Sebastian Jh Bredie

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Frequent home blood pressure (BP) measurements result in a better estimation of true BP. However, traditional cuff-based BP measuring is troublesome for patients. Objective: To evaluate the use and efficacy of a new cuffless device (Checkme) for ambulatory systolic blood pressure (SBP) measurement. Methods: A mixed-method study in hypertensive patients. Reliability of Checkme SBPs was analyzed quantitatively by intra-user reproducibility and comparability to a classic home BP monitor. Correct use by the patients was checked with video. Patients reported experience with qualitative semi-structured interviews and user-friendliness was assessed using a validated questionnaire. Results: 1020 Checkme SBP measurements were performed in 11 hypertensive patients. Duplicate SBPs showed a high intra-user correlation (R=0.86, p<0.01). SBP of the Checkme did not correlate well with those of the different home monitors being used (R=0.47, p<0.01). However, the mean SBP’s of the Checkme and of the home monitors over 3 weeks follow-up were highly correlated (R=0.75, p<0.01). 36.4% (n=4) of the participants performed the Checkme measurements without any mistakes. The mean SUS score was 86.4 (SD=8.3). The most important facilitator was the ease of use of the Checkme. Most important barriers included the absence of diastolic BP and the incidental difficulties in obtaining an SBP result. Conclusions: Given the good intra-user reproducibility, user-friendliness and patient experience, which all facilitate patients to perform frequent measurements, cuffless BP monitoring may change the way patients are measuring their home BP in the context of ambulant hypertension management. Clinical Trial: NA


  • Wireless and continuous monitoring of vital signs in patients at the general ward

    by Mariska Weenk, Mats Koeneman, Tom H. van de Belt, Lucien J.L.P.G. Engelen, Harry van Goor, Sebastian J.H. Bredie